ADRO Chinook Therapeutics Inc

Aduro Biotech Stockholders Approve Merger Agreement with Chinook Therapeutics

Aduro Biotech Stockholders Approve Merger Agreement with Chinook Therapeutics
EN
01/10/2020

Underlying

ADROChinook Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Chinook Therapeutics Inc

 PRESS RELEASE
Free
ADRO Chinook Therape...

Aduro Biotech Stockholders Approve Merger Agreement with Chinook Thera...

Aduro Biotech Stockholders Approve Merger Agreement with Chinook Therapeutics

October 1, 2020 1 EN
 PRESS RELEASE
Free
ADRO Chinook Therape...

Aduro Biotech Provides Business Update and Reports Second Quarter 2020...

Aduro Biotech Provides Business Update and Reports Second Quarter 2020 Financial Results BERKELEY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the A Proliferation Inducing Ligand (APRIL) and Stimulator of Interferon Genes (STING) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2020. “The second quarter of 2020 was highlighted by the announceme...

August 3, 2020 1 EN
 PRESS RELEASE
Free
ADRO Chinook Therape...

Aduro Biotech Announces First Patient Dosed in Phase 1 Study of BION-1...

Aduro Biotech Announces First Patient Dosed in Phase 1 Study of BION-1301 in IgA Nephropathy BERKELEY, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the first patient with IgA nephropathy has been dosed in a Phase 1 clinical trial of BION-1301, an investigational humanized IgG4 monoclonal anti...

June 24, 2020 1 EN
 PRESS RELEASE
Free
ADRO Chinook Therape...

Aduro Biotech Presents Nonclinical and Phase 1 Healthy Volunteer Data ...

Aduro Biotech Presents Nonclinical and Phase 1 Healthy Volunteer Data for BION-1301 at the 57th ERA-EDTA Virtual Congress BION-1301 was well-tolerated, with no serious adverse events (SAEs), treatment discontinuations or events meeting stopping criteria, across a wide range of dosesPharmacokinetics (PK) of BION-1301 were generally dose-proportional with an estimated half-life of 33 days, suggesting the potential for monthly dosing BION-1301 dose-dependently and durably reduced IgA and IgM, and to a lesser extent, IgG, providing a pharmacodynamic (PD) window to potentially exploit reductions...

June 2, 2020 1 EN
 PRESS RELEASE
Free
ADRO Chinook Therape...

Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agre...

Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agreement – Combined Company Will Operate as Chinook Therapeutics and Advance Pipeline of Clinical-Stage Programs in Kidney Diseases, Led by Atrasentan and BION-1301 in IgA Nephropathy – Combined Company Will be Well-Funded With Cash Position of ~$200 Million Expected at Closing, Including $25 Million in Additional Investment Committed by Chinook’s Existing Investors – Multiple Clinical and Regulatory Pipeline Milestones Planned for Combined Company Over the Next 12-18 Months – Companies to Host Joint Conference Call on Tu...

June 2, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch